In a nutshell The present article reviews new and prospective treatments for castration-resistant prostate cancer (CRPC). Sipuleucel-T, Cabazitaxel, Denosumab and Abiraterone are novel therapies approved in the last few years for CRPC, while several other therapeutic agents such as MDV3100, Alpharadin and...
Read MoreCurrent treatment status-Undergoing active treatment,Partial response Posts on Medivizor
